Board of Directors
Sylvie Grégoire – Board Chair
Sylvie Grégoire, has over 25 years of international experience in the biotech and pharmaceutical industries. Sylvie was President of Shire Human Genetic Therapies (HGT), a business unit of Shire plc that focuses on Rare Diseases. Under her leadership, the business unit grew from $300M to $1.5B. Prior to joining Shire HGT, Sylvie was Executive Chairwoman of IDM Pharma. She was previously CEO of GlycoFi, a privately held protein technology company, held executive positions at Biogen Inc., and worked at Merck & Co. in the US and abroad. Sylvie is also a non-executive member of the board of 3 public companies: Galenica, a Swiss pharmaceutical company, NovoNordisk a Danish pharmaceutical company and PerkinElmer an instrumentation and diagnostics company. She has a depth of experience in the management of commercial operations, manufacturing and regulatory affairs. Sylvie holds a Bachelor of Science degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.
MARC DE GARIDEL – CEO, Corvidia Therapeutics
Marc de Garidel is the Chief Executive Officer of Corvidia Therapeutics. Prior to joining Corvidia, Marc was the Chairman and Chief Executive Officer of Ipsen SA between 2010 and 2016 where he led the company through a significant transformation and spearheaded growth of operations in the United States. Prior to his experience at Ipsen SA, Marc spent 15 years with the multinational biopharmaceutical company Amgen. Based primarily in Europe, Marc helped Amgen establish and build a significant business in nephrology and oncology, achieving leadership positions for several portfolio products. He began his career with Eli Lilly and Company where he worked in the United States, France and Germany. In Europe, Marc has played a prominent role in not-for-profit organizations such as the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is currently the president of G5 Sante’. Marc served on the Board of Directors for Vifor Pharmaceuticals AG as a member and in 2018 as Vice Chair. He remains Chair of the Board of Directors for Ipsen SA. Marc holds a Master’s degree in civil engineering from École Spéciale des Travaux Publics in Paris and an executive MBA from Harvard Business School.
Graziano Seghezzi – Sofinnova Partners
Graziano Seghezzi is a Partner at Sofinnova Partners which he joined in 2006. He seeded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano also seeded and is on the Board of MISSION Therapeutics (United Kingdom), Crescendo Biologics (United Kingdom) and Hookipa Biotech (Austria). He promoted and is on the Board of BiovelocITA, Italy’s first biotech accelerator. Graziano started his career in venture capital in 2001 at Sofinnova Partners and then joined Index Venture in 2003. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from RSM-Erasmus University (Netherlands).
Seth Harrison – Apple Tree Partners
Seth Harrison is the managing partner of Apple Tree Partners and serves as Executive Chairman of Braeburn Pharmaceuticals. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He is currently also Chairman of Tokai Pharmaceuticals, Chairman of Aileron Therapeutics and Deputy Chairman of Heartware International, all companies he founded. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York. From 2002 – 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.
Tyrell Rivers - AstraZeneca
Dr. Tyrell Rivers is an Executive Director within AstraZeneca’s corporate development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing and, at Merck & Company, Inc. where he led the technical support for multiple commercial vaccine franchises, subsequently directing global business initiatives for accessing key technologies in research and development.
Dr. Rivers earned his Bachelor of Science degree in chemical engineering from the Massachusetts Institute of Technology and his PhD in chemical engineering from University of Texas at Austin. He earned his MBA from the New York University Stern School of Business. Dr. Rivers serves on the Board of Directors for G1 Therapeutics (GTHX), Viela Bio and Armaron Bio Ltd. He is a board observer for several private companies.